Since, c-Myc is heavily expressed and plays a pivotal role in enzalutamide-resistant prostate cancer and is tightly regulated by 5-Lox, our findings indicate that inhibition of 5-Lox by MK591 may turn out to be an effective strategy to overcome enzalutamide-resistance in prostate cancer via downregulation of the c-Myc oncogene and selective induction apoptosis in ERPC cells (Fig. 7). This evidence concerns the gene MYC and prostate carcinoma.